Abstract
[3] However, PFA ependymoma mostly occurs in infants and young children, to whom ionizing radiation may pose great risks. [...]there is still an urgent need in the treatment of PFA ependymoma patients who could not or are reluctant to receive radiotherapy. [...]the half-maximal inhibitory concentration (IC50) of cisplatin was reduced from 451.00 nmol/L to 62.52 nmol/L in C67-KO cells with CXorf67 re-expression restored when niraparib was used [Figure 1A]. See PDF] In summary, the treatment of PARP inhibitors combined with chemotherapy undoubtedly opens a new avenue for PFA ependymoma patients, especially those who cannot or are reluctant to receive radiotherapy. [...]it offers an option as a salvage regimen for recurrent PFA patients with CXorf67 high expression, for which no standard medical treatment exists, although further clinical researches are required.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang 310024, China
2 Department of Neurosurgery, Children’s Hospital of Fudan University, Shanghai 201102, China
3 Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang 310024, China
4 School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
5 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China
6 State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang 310024, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China